Home|Journals|Articles by Year|Audio Abstracts
 

Review Article

J App Pharm Sci. 2023; 13(7): 85-101


Nuclear receptors and other molecular targets in type 2 diabetes mellitus

Deepa Sugumar, Emdormi Rymbai, Soumya Vasu, Divakar Selvaraj.




Abstract
Cited by 1 Articles

Diabetes is a group of metabolic disorders characterized by chronic hyperglycemia and glucose intolerance. Diabetes occurs because of defects in insulin secretion, insulin action, or both. Type 2 diabetes mellitus (T2DM), with a prevalence of more than 95%, is the most prevalent form of diabetes. Over the years, the effectiveness of the drugs used to treat diabetes has reduced. For this reason, targeting newer molecular targets might lead to the effectiveness of drugs. Over the years, there has been a great interest in targeting nuclear receptors for the treatment of T2DM. Some of these targets have been applied at the clinical level. However, other molecular targets belonging to G-coupled protein receptors, enzymes, and kinases have also been explored. Hence, in this review, we will discuss a few potential targets that have been applied clinically or could be the target for the treatment of T2DM.

Key words: nuclear receptors, type 2 diabetes mellitus, peroxisome proliferator-activated receptors, androgen receptor, vitamin d receptor






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.